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ABSTRACT
Background. Strategies for the treatment of recurrence
after initial curative esophagectomy are increasingly being
recognized. The aim of this study was to identify prog-
nostic factors that affect survival in patients with
recurrence and to evaluate treatment strategies.
Methods. A prospective database (2003–2013) was used
to collect consecutive patients with esophageal carcinoma
treated with initial curative esophagectomy. Locations,
symptoms, and treatment of recurrence were registered.
Post-recurrence survival was defined as the time between
the first recurrence and death or last follow-up.
Results. Of the 335 selected patients, 171 (51 %) developed
recurrence. Multivariable analysis identified distant recur-
rence as opposed to locoregional recurrence [hazard ratio
(HR) 2.15, 95 % confidence interval (CI) 1.27–3.65;
p = 0.005], more than three recurrent locations (HR 2.42,
95 % CI 1.34–4.34; p = 0.003), and treatment (HR 0.29,
95 % CI 0.20–0.44; p\ 0.001) as independent prognostic
factors associated with post-recurrence survival. Primary
tumor characteristics, including neoadjuvant therapy, histo-
logical type, pTN stage, and radicality, did not independently
influence post-recurrence survival. Treatment was initiated in
62 patients (37 %) and included chemotherapy, radiotherapy,
and/or surgery. Median post-recurrence survival of all patients
was 3.0 months (range 0–112). In total, six patients (4 %)
were still disease-free following treatment, indicating cure.
Conclusions. In patients treated for esophageal cancer at
curative intent, distant recurrence and more than three
recurrent locations were independent prognostic factors
associated with worse post-recurrence survival, irrespec-
tive of primary tumor characteristics. Although survival
after recurrence was poor, treatment can prolong survival
and can even lead to cure in selected patients.
Esophageal carcinoma is the sixth leading cause of
cancer-related mortality worldwide and the incidence is
rapidly increasing.1,2 Multimodality treatment combining
neoadjuvant chemo(radio)therapy and surgical resection
has improved the prognosis for resectable nonmetastatic
disease;3 however, more than half of the patients develop
recurrence within 3 years after treatment with curative
intent.4–7 The prognosis of recurrent esophageal cancer is
poor, with a median survival of 3–10 months after devel-
oping a recurrence.4,8–10 Therefore, detecting prognostic
factors affecting post-recurrence survival and determining
effectiveness of treatment strategies for recurrence are of
high importance. Treatment can be attempted in a fair
number of patients with recurrent disease and may include
chemotherapy, radiotherapy, surgery, or a combina-
tion.9,11,12 However, the optimal treatment strategy for
esophageal cancer patients with recurrent disease is not yet
established and patients respond differently to treatment,
with a wide range in long-term survival.12
The main aim of this study was to investigate prognostic
factors that affect survival in patients diagnosed with
recurrent disease after prior esophagectomy with curative
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intent for esophageal carcinoma. In addition, a second aim
was to evaluate the different treatment strategies applied.
METHODS
Patients
In this single-center cohort study, patients were selec-
ted from a prospectively assembled database at the
University Medical Center Utrecht, Utrecht, The Nether-
lands. Between October 2003 and December 2013, a total
of 379 consecutive patients underwent esophagectomy
with curative intent for esophageal carcinoma. Patients
with an unresectable tumor (cT4b) or metastatic disease
(M1) detected intraoperatively were excluded (n = 22), as
were patients deceased within 90 days after surgery or
during hospitalization (n = 22). Of the remaining 335
patients, 171 were diagnosed with recurrent disease and
were included in the current study. All patients were
discussed at a multidisciplinary tumor board meeting
preoperatively, postoperatively, and after developing
recurrent disease. Institutional Review Board approval
was obtained, and the informed consent requirement was
waived for this study.
Treatment
Eligible patients with locally advanced disease (cT C2
or cN?) and without clinical evidence of metastatic dis-
ease (cM0) received either perioperative chemotherapy or
neoadjuvant chemoradiation according to the Dutch
guidelines. Eligible patients were[18 years of age, had a
WHO performance status B2, and did not lose[10 % of
their body weight. Before 1 June 2012, the standard
treatment for patients with esophageal carcinoma con-
sisted of perioperative chemotherapy (epirubicin,
cisplatinum, and 5-fluorouracil),14 and after that patients
underwent neoadjuvant chemoradiation (carboplatin
AUC2 and paclitaxel 50 mg/m2 weekly during 5 weeks
concomitant with 41.4 Gy (23 9 1.8 Gy).3 Before 2008,
neoadjuvant therapy was not part of the standard protocol
and most patients were operated on without this treat-
ment. Patients not eligible for neoadjuvant treatment were
treated with esophageal resection alone. After
esophagectomy with en bloc lymphadenectomy, all
patients underwent gastric tube reconstruction with a left-
sided cervical anastomosis.
Histopathological Analysis
The resected specimens were reviewed by experienced
pathologists in accordance with the TNM-7 staging system
of the AJCC.13 Resection margins were evaluated using the
definitions of the College of American Pathologists.15,16
Follow-Up and Definition of Recurrence
After esophagectomy, patients were followed at the
outpatient clinic with an interval of 3 months in the first
year, 6 months in the second year, and 12 months there-
after until discharge after 5 years of follow-up, which
consisted of medical history and physical examination. In
case of clinical suspicion of tumor recurrence, diagnostic
imaging was performed. Recurrence was confirmed by
histopathological biopsy or clinical follow-up, and only the
initial number and sites of recurrences were evaluated. The
pattern of recurrence was classified as locoregional, distant,
or a combination of both. Recurrences at the anastomotic
site or within the area of previous resection and nodal
clearance in the mediastinum or upper abdomen were
classified as locoregional recurrence, while distant recur-
rence was defined as recurrence in distant organs, pleura or
peritoneal cavity, or distant lymph nodes. Disease-free
survival was defined as the time between the day of surgery
and day of recurrent disease, and post-recurrence survival
was defined as the time between the first recurrence and
death or last follow-up.
Treatment of Recurrence
Treatment for recurrent disease was discussed at a
multidisciplinary tumor board meeting and was recom-
mended if the patient was eligible. General considerations
regarding eligibility included patient condition, location of
recurrences, prior toxicity from chemotherapy or radio-
therapy, and patient’s wish. Treatment consisted of
chemotherapy, radiotherapy, and/or surgery focused on
tumor reduction. Radiotherapy focused on tumor reduction
was defined as radiotherapy with a radiation dose[30 Gy,
excluding palliative radiotherapy for bone metastases. In
all other cases, patients were treated with best supportive
care.
Statistical Analysis
To assess prognostic factors for post-recurrence sur-
vival, univariable and multivariable analyses by means of
Cox proportional hazard models were used, providing
hazard ratios (HRs) with 95 % confidence intervals (CIs).
All variables with a p value\0.20 in univariable analysis
were entered in a multivariable analysis. Kaplan–Meier
survival curves were constructed for the prognostic factors
that remained significantly associated with post-recurrence
survival in multivariable analysis. A p value \0.05 was
considered statistically significant. All statistical analyses
Prognosis and Treatment After Diagnosis of Recurrent Esophageal S1293
were performed using IBM SPSS version 21 for Windows
(IBM Corporation, Armonk, NY, USA).
RESULTS
Patient Characteristics
Median follow-up of the 335 consecutive patients trea-
ted with esophagectomy during the study period was
22.0 months (range 2–135). Of all patients, 171 (51 %)
developed recurrent disease, and these patients were
included in the current study. The clinical and
histopathological characteristics of these 171 patients are
shown in Table 1. Mean age was 63 years (standard
deviation 8.8) and most patients were male (n = 131,
77 %). Perioperative chemotherapy was administered in 63
patients (37 %) and neoadjuvant chemoradiation in 35
patients (21 %). The surgical procedure consisted of a
transthoracic approach in 132 patients (77 %) and a tran-
shiatal approach in the remaining 39 patients (23 %).
Tumor histology was adenocarcinoma in 136 patients
(80 %), and histopathology revealed CpT3 (n = 129,
75 %) and pN? disease (n = 123, 72 %) in the majority of
patients. Of all patients who developed a recurrence, 139
(81 %) underwent a microscopically radical (R0) resection.
Pattern of Recurrence
Median time to recurrence was 9.0 months (range 1–86)
and 164 patients (96 %) developed recurrence within
3 years after surgery. The most common presenting
symptoms were pain (n = 38, 22 %), malaise (n = 23,
14 %), dysphagia (n = 21, 12 %), and anorexia (n = 21,
12 %). The diagnosis of recurrent disease was based on
computed tomography (CT) findings in 118 patients
(69 %), whereas in other patients the diagnosis was made
with either endoscopic ultrasound (EUS), upper endoscopy,
positron emission tomography (PET), or magnetic reso-
nance imaging (MRI). The type of recurrence and the
number of locations are presented in Table 2. Distant
recurrence was the most common type of recurrent disease
(n = 76, 44 %), and the liver was the most commonly
affected site (n = 50, 15 %).
Factors Affecting Post-recurrence Survival
Median post-recurrence survival was 3.0 months (range
0–112), and the overall 1- and 2-year post-recurrence sur-
vival rates were 17 and 7 %, respectively. Nodal status,
type of recurrence, number of locations, time to recurrence,
and treatment of recurrence were significantly associated
with post-recurrence survival in univariable analysis
(Table 3; Fig. 1). In multivariable analysis, distant recur-
rence (HR 2.15, 95 % CI 1.27–3.65; p = 0.005), more than
three recurrent tumor locations (HR 2.42, 95 % CI
TABLE 1 Clinical and histopathological characteristics of 171
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1.34–4.34; p = 0.003), and treatment (HR 0.29, 95 % CI
0.20–0.44; p\ 0.001) were identified as independent
prognostic factors associated with post-recurrence survival
(Table 3). The median post-recurrence survival of patients
with distant and locoregional recurrence was 2.0 months
and 12.0 months respectively. This was respectively 2.0
and 6.0 months for patients with more than three recurrent
tumor locations and a solitary recurrence. Patients who
received treatment focused on tumor reduction had a
median post-recurrence survival of 9.0 months compared
with 2.0 months in patients treated with best supportive
care. Primary tumor characteristics, including neoadjuvant
therapy, histological type, pTN stage, and radicality of
resection, did not independently influence post-recurrence
survival in multivariable analysis.
Treatment of Recurrence
Patients receiving best supportive care (n = 109, 63 %)
were mainly either not eligible for treatment due to a poor
performance status (n = 63, 37 %) or refused treatment
(n = 29, 17 %). Some patients were not eligible due to
prior toxicity of the neoadjuvant treatment regimen (n = 4,
4 %) or tumor location (n = 4, 4 %). Treatment focused on
tumor reduction was applied in 62 patients (37 %)
(Table 2). Patients with locoregional recurrence (n = 19,
70 %) and solitary recurrence (n = 24, 49 %) more often
received treatment focused on reduction compared with
those with distant recurrence (26, 34 %) and more than
three recurrent tumor locations (n = 14, 23 %). Different
chemotherapy regimens were administered in 41 patients,
with most patients receiving a combination of epirubicin,
cisplatin, and capecitabine (n = 20, 48 %). After treatment
with chemotherapy only, two patients (5 %) showed a
clinically complete tumor regression—one patient had a
solitary metastasis in the liver, and the other had a solitary
locoregional recurrence in the gastric conduit and truncal
node. Both patients were alive at last follow-up (35 and
112 months after diagnosis of recurrence).
In 13 of 171 patients (8 %), surgical resection of the
recurrence was performed (Table 4), with most of these
patients having a solitary recurrence (n = 9, 69 %) at a
distant location (n = 11, 85 %). Surgical resections are
outlined in Table 4; five patients (38 %) underwent
metastasectomy of a brain lesion. Median post-recurrence
survival in patients who underwent resection was
11 months (95 % CI 4.5–17.5), and in 11 of 13 patients
(85 %) the resection was performed with curative intent.
Of these patients, 4 of 11 (36 %) were still alive at last
follow-up, with a follow-up of 5, 46, 53, and 87 months
after the diagnosis of their recurrence, whereas the
remaining seven patients (64 %) deceased due to disease
progression.
DISCUSSION
In this single-center cohort study, 171 patients with
recurrent disease after treatment with curative intent for
esophageal carcinoma were analyzed and factors affecting
post-recurrence survival were evaluated. Distant recurrence
and more than three recurrent locations were identified as
independent prognostic factors associated with a worse
post-recurrence survival, irrespective of primary tumor
characteristics. Furthermore, treatment focused on tumor
reduction, as opposed to best supportive care, prolonged
TABLE 2 Location and treatment recurrence of 171 patients with
recurrent disease after esophagectomy with curative intent
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survival in eligible patients and a selected group of patients
were treated curatively.
This study confirms the poor prognosis of recurrent
esophageal cancer reported in other series4,8,9,10 with a
median post-recurrence survival of 3.0 months and a
2-year survival rate of only 7 %. Hence, understanding of
the prognostic factors influencing survival is important in
identifying patients who could have an improved post-
recurrence survival by selecting them for the appropriate
treatment. In accordance with the literature, distant recur-
rence was associated with a worse survival in this study,
reflecting aggressive tumor biology.6,12,17 Furthermore, this
study showed that patients with more than three recurrent
tumor locations had a worse post-recurrence survival
compared with those with less involved locations, which
could also be explained by the more aggressive behavior of
TABLE 3 Univariable and multivariable analysis of potential prognostic factors for survival after diagnosis of recurrent esophageal carcinoma
HR 95 % CI p-Valuea HR 95 % CI p-Valueb
Age (years) 1.02 1.00–1.04 0.055 1.00 0.99–1.02 0.670
Neoadjuvant therapy
None Reference – – Reference – –
Chemotherapy 1.39 0.98–1.99 0.067 1.02 0.70–1.49 0.936
Radiotherapy 3.45 0.47–25.23 0.222 7.85 0.99–62.54 0.052
Chemoradiation 1.26 0.82–1.94 0.297 0.84 0.50–1.41 0.512
Histological type
Adenocarcinoma Reference – –
Squamous cell carcinoma 1.24 0.84–1.84 0.272
Other 1.10 0.15–7.93 0.922
pT stage
T0 Reference – – Reference – –
T1–2 0.47 0.21–1.06 0.067 0.60 0.25–1.41 0.243
T3–4 0.70 0.34–1.45 0.341 0.78 0.34–1.76 0.545
pN stage
N0 Reference – – Reference – –
N1 1.80 1.18–2.75 0.007 1.50 0.95–2.37 0.080
N2–3 1.35 0.91–1.99 0.131 1.10 0.70–1.73 0.689
Radicality
R0 Reference – –
R1 1.20 0.81–1.77 0.363
Type of recurrence
Locoregional Reference – – Reference – –
Distant 2.10 1.30–3.41 0.003 2.15 1.27–3.65 0.005
Combined 2.54 1.55–4.16 \0.001 1.58 0.89–2.81 0.120
Number of locations
1 Reference – – Reference – –
2–3 1.21 0.81–1.79 0.357 1.30 0.83–2.00 0.250
[3 2.20 1.46–3.32 \0.001 2.42 1.34–4.34 0.003
Time to recurrence (months) 0.98 0.96–1.00 0.013 0.99 0.98–1.01 0.263
Treatment of recurrence
Best supportive care Reference – – Reference – –
Treatment focused on tumor reduction 0.27 0.19–0.38 \0.001 0.29 0.20–0.44 \0.001
Analysis was performed using a Cox regression model
Bold values indicate statistically significant (e.g. p\ 0.05). All variables with a p value \0.2 from univariable analysis were used for
multivariable analysis
HR hazard ratio, CI confidence interval
a Univariable analysis
b Multivariable analysis
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multiple recurrences. The survival of patients with more
than three recurrent locations was extremely poor, with a
median survival of 2.0 months after the diagnosis of
recurrence compared with 6.0 months in patients with a
solitary recurrence. The majority of patients had a poor
clinical condition at the time of diagnosis of recurrence and
were therefore considered ineligible for treatment focused
on tumor reduction. The patients who underwent treatment
had a significantly prolonged survival, which is likely
explained by a combination of appropriate patient selection
and treatment effectiveness.
As has been reported in previous studies,4,9,18 all dif-
ferent treatment strategies resulted in a prolonged survival
in the current study. This finding suggests that all patients
with recurrent disease should be stimulated to undergo
treatment if the condition of patients allows it. Median
post-recurrence survival in the treated group was
9.0 months compared with 2.0 months for those who were
treated with best supportive care. It needs to be acknowl-
edged that the majority of patients who received best
supportive care were not eligible for therapy, causing bias
through selection-by-indication in this comparison.
Nonetheless, most patients who were not eligible had
advanced disease (i.e. distant recurrence or more than three
recurrent locations), which reflects high dependency of the
patient’s condition on the site and number of recurrent
tumors.
Patients were treated with various therapies, of which
chemotherapy was the most commonly applied. The benefit
of a surgical resection of recurrent esophageal carcinoma is
not yet completely elucidated. A few reports showed
improved survival after surgical resection; 11,19,20 however,
in most studies the resection was combined with either
chemotherapy or radiotherapy and was performed in only a
small number of patients. Also in this study, a small group
of patients (n = 13) underwent resection of their recur-
rence, the majority (n = 9) of whom had an
oligometastasis. Patients with oligometastases represent a
special tumor behavior that is likely to gain from local
control. In other types of cancer, the current literature also
shows a survival benefit with long disease-free survival
from local control with surgery for patients with
oligometastases.21,22 Importantly, four patients had com-
plete tumor remission after the resection and were still
alive at last follow-up. Other studies also reported long-
term survival after treatment of recurrent disease for eso-































































































































FIG. 1 a Type of recurrence, b number of tumor locations, and
c type of management were identified as independent prognostic
variables for post-recurrence survival in 171 patients with recurrent
disease after curative esophagectomy. Survival curves were plotted
using the Kaplan–Meier method
b
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favorable outcome can be expected after surgical resection
in a selected patient group, especially for those with soli-
tary or localized recurrence of esophageal cancer.
Although treatment of recurrence resulted in prolonged
survival, the majority of patients (63 %) received best
supportive care. This is in contrast with some other studies
where the proportion of patients receiving best supportive
care ranged from 12 to 44 %.9,11,17,26, 27An explanation for
the high percentage of best supportive care in this cohort
could lie in the follow-up strategy; the current follow-up
strategy is based on the existing literature showing that
routine diagnostic imaging is of no benefit with regard to
survival and costs.28 Furthermore, the consensus-based
guidelines from the National Comprehensive Cancer Net-
work also suggest that diagnostic imaging should only be
performed when clinically indicated.29 Hence, this follow-
up strategy is widely performed in The Netherlands;
however, it could have resulted in more advanced recurrent
tumor stages at the moment of diagnosis. Since the
patient’s condition is largely determined by the number and
site of recurrences, patients with multiple metastases are
often not eligible for therapy; therefore, the follow-up
strategy may need revision according to the findings of the
current study. In light of new insights into the concept of
oligometastases and the new combined treatment options,
we suggest routinely performing a follow-up of patients
with PET CT in the first 6–12 months following primary
treatment.30 Another explanation for the high ‘best sup-
portive care’ rate could be the large proportion of patients
(27 %) who refused any form of treatment. In most other
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studies, only a fraction of patients did not receive treatment
based on patient’s choice.17,26,27According to the results of
the current study, eligible patients might be encouraged to
have treatment focused on tumor reduction to improve their
survival. Unfortunately, no information on quality of life,
which is of paramount importance in patients being treated
with palliative intent, was obtained from patients who were
treated for recurrence.
CONCLUSIONS
Survival after developing a recurrence after esophagec-
tomy with curative intent is poor. Distant recurrence and
more than three recurrent locations were identified as inde-
pendent factors associated with a worse survival,
irrespective of primary tumor characteristics. Treatment
focused on tumor reduction using various strategies con-
tributed to a prolonged survival in all patients. Hence,
stronger focus is needed to improve patient selection for
treatment in recurrent esophageal carcinoma. Additionally,
in a small group of patients (4 %), curative treatment of
recurrent esophageal carcinoma appears possible.
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